As shown in Figure 8, we found that the benzimidazole derivatives have activity on four targets, namely GSK3β, BACE1, AChE, and Aβ anti-aggregation, which are targets that have been identified when multitarget compounds for AD have been proposed [98,99]. This evidence concerns the gene BACE1 and Alzheimer disease.